SciSparc invests C$2.7 million in NeuroThera, holding 44.6% of the shares after C$5.4 million financing round.
Quiver AI Summary
SciSparc Ltd. has invested C$2.7 million in its majority-owned subsidiary, NeuroThera Labs Inc., which recently completed private placements raising a total of C$5.4 million. This investment accounts for 50% of the total funds raised, allowing SciSparc to acquire 22,500,000 units at C$0.12 per unit. Following this financing round, SciSparc holds approximately 44.6% of NeuroThera's common shares, valued at around C$30 million. NeuroThera plans to use the proceeds for general working capital and other corporate expenses. The company focuses on developing treatments for central nervous system disorders, including programs for Tourette syndrome, Alzheimer's disease, and autism spectrum disorder.
Potential Positives
- SciSparc has invested C$2.7 million in NeuroThera, representing 50% of the total gross proceeds raised in a significant financing round.
- Following the investment, SciSparc holds approximately 44.6% of NeuroThera’s issued and outstanding common shares, valued at around C$30 million.
- The financing positions NeuroThera to enhance its operations and development programs, which focus on novel treatments for central nervous system disorders.
- The inclusion of warrants with an acceleration provision upon Nasdaq listing indicates potential for increased value and liquidity for SciSparc’s investment in NeuroThera.
Potential Negatives
- Holding approximately 44.6% of NeuroThera's shares indicates a significant level of investment risk for SciSparc, as a large portion of its value is tied to the performance of a single subsidiary.
- The reliance on private placements for funding may signal challenges in obtaining financing through traditional means, raising concerns about overall financial stability.
- The forward-looking statements include various risks and uncertainties, which suggests potential volatility and lack of guaranteed success in its ongoing drug development programs.
FAQ
What was the total amount raised in NeuroThera's financing?
NeuroThera raised aggregate gross proceeds of C$5.4 million through two tranches of non-brokered private placements.
How much did SciSparc invest in NeuroThera's financing?
SciSparc invested C$2.7 million, which represents 50% of the total gross proceeds raised in the financing.
What percentage of NeuroThera does SciSparc own after the financing?
After the financing, SciSparc holds approximately 44.6% of NeuroThera’s issued and outstanding common shares.
What will NeuroThera use the financing proceeds for?
NeuroThera plans to use the net proceeds from the financing for general working capital and other corporate expenses.
What are SciSparc's focuses in pharmaceutical developments?
SciSparc focuses on developing cannabinoid pharmaceuticals and enhancing its portfolio of technologies related to central nervous system disorders.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SPRC Insider Trading Activity
$SPRC insiders have traded $SPRC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SPRC stock by insiders over the last 6 months:
- ITSCHAK SHREM sold 462 shares for an estimated $4,620
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SPRC Hedge Fund Activity
We have seen 8 institutional investors add shares of $SPRC stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HRT FINANCIAL LP added 21,235 shares (+inf%) to their portfolio in Q2 2026, for an estimated $117,217
- VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC removed 20,224 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $74,019
- JANE STREET GROUP, LLC added 16,496 shares (+inf%) to their portfolio in Q2 2026, for an estimated $91,057
- CITADEL ADVISORS LLC added 11,065 shares (+inf%) to their portfolio in Q2 2026, for an estimated $61,078
- XTX TOPCO LTD removed 10,331 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $37,811
- UBS GROUP AG added 1,372 shares (+43.6%) to their portfolio in Q2 2026, for an estimated $7,573
- JPMORGAN CHASE & CO added 211 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,164
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera’s issued and outstanding common shares following the financing
TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.
SciSparc participated in the financing with a C$2.7 million investment, representing 50% of the total gross proceeds raised. SciSparc subscribed for 22,500,000 units at a price of C$0.12 per unit, with each unit consisting of one common share of NeuroThera and one common share purchase warrant. The warrants are exercisable for three years and are subject to an acceleration provision whereby, upon the securities of NeuroThera being approved for trading on the Nasdaq Stock Market, the expiry date of 50% of the unexercised warrants will be accelerated and NeuroThera will provide three business days advance written notice to holders of such accelerated expiry date.
Following the financing, SciSparc will hold approximately 44.6% of NeuroThera’s issued and outstanding common shares, SciSparc’s stake in NeuroThera is valued at approximately C$30 million.
NeuroThera intends to use the net proceeds from the financing for general working capital purposes and other corporate and administrative expenses.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
About NeuroThera Labs Inc.
NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the intended use of proceeds by NeuroThera from its financing. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
[email protected]
Tel: +972-3-6167055
